Home Print this page Email this page
Users Online: 424


 
 Table of Contents  
REVIEW ARTICLE
Year : 2015  |  Volume : 7  |  Issue : 2  |  Page : 27-34

Genetics and diabetic microangiopathy


1 Medical Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Eye, Medical Faculty of Medicine, Bu Ali-Sina Hospital, Mazandaran University of Medical Sciences, Mazandaran, Iran

Date of Web Publication12-Nov-2015

Correspondence Address:
Ahmad Ahmadzadeh Amiri
Department of Eye, Bu Ali-Sina Hospital, Medical Faculty of Medicine, Mazandaran University of Medical Sciences, Mazandaran
Iran
Login to access the Email id

DOI: 10.4103/1858-540X.169374

Rights and Permissions
  Abstract 

Human vital organ systems may be affected by diabetic microvascular complications (DMC), lead to public health difficulty. Recent evidence shows genetic factors provide to the genetic and structural variants, and/or variability in disease severity play important roles in the development of DMC among the patients with similar risk factors. Several genetic loci have discovered that figure the risk of DMC as detected by genetic linkage studies. Genetic variants demonstrate for susceptibility to DMC as detected by genetic association studies. Copy number variation and interactions of gene Χ environment have been discovered by compelling analysis of structural variants. Mitochondrial DNA also acts a definite role in the development of DMC. Sequencing technologies have light important horizon on detecting rare and common genetic loci. This review focuses on the common science of the genetic context of DMC. Finally, recognition of genes or genetic loci and structural variants providing to risk of or guarding from DMC will help intuition the underlying mechanism of DMC, with conclusive suggestions for the evolvement of new medicine for diabetes mellitus complications.

Keywords: Diabetes mellitus, genetic, microangiopathy


How to cite this article:
Ahmadzadeh-Amiri A, Amiri AA. Genetics and diabetic microangiopathy. Sudanese J Ophthalmol 2015;7:27-34

How to cite this URL:
Ahmadzadeh-Amiri A, Amiri AA. Genetics and diabetic microangiopathy. Sudanese J Ophthalmol [serial online] 2015 [cited 2019 Jul 15];7:27-34. Available from: http://www.sjopthal.net/text.asp?2015/7/2/27/169374


  Introduction Top


Diabetes burdens the major cause of morbidity and mortality in the world. Diabetic patients have approximately a 7-year shorter life expectancy; as compared with nondiabetic population. [1] Microvascular complications of diabetes implicate multiple organ systems, causing diabetic retinopathy (DR), diabetic kidney disease (DKD), and/or diabetic neuropathy (DN). [2],[3],[4]

The most important sight-threatening complications are DR. The two most important factors in the development of retinopathy are the duration of diabetes and glycemic control. [5],[6] However; it may be nonexistent in some poor controlling patients even over a long time while others may evolve retinopathy in a relatively short period of time despite well-controlled blood sugar. Genetic susceptibility could discuss the occurrence of retinopathy. Several evidence encourage for a genetic role for retinopathy derives from twin and family studies. [7],[8],[9] Diabetes Control and Complications Study (DCCT) [10] and the United Kingdom Prospective Diabetes Study have been clearly discussed the importance of metabolic control in the prevention of diabetic complications. [11] However, in the analysis of both studies, retinopathy developed in groups of patients who were fairly good control and others preserved despite poor glycemic control. [8]

The classic descriptions of DKD show that it forms more than a decade after diabetes appearance. Microalbuminuria is the earliest sign of DKD (>30 mg/day), which with time progresses to macroalbuminuria (>300 mg/day) and diminish in glomerular filtration rate (GFR), ultimately resulting in end-stage renal failure (ESRD). [12] Diabetic nephropathy shows a strongly correlate with retinopathy in patients with type 1 diabetes mellitus (T1DM). DKD is a clinical diagnosis as detected by macroalbuminuria in a diabetic patient, with ruled out other causes of albuminuria. As recorded by recent reports; microalbuminuria can revert, and subsets of patients have ongoing DKD in the absence of proteinuria. [13],[14],[15] Some patients with diabetes will not progress DKD, even in the setting of poorly control glycemia, denoting an individual susceptibility. This role is well-founded by the familial aggregation study of kidney disease. [16] Genome-wide association studies (GWAS) emphasize genetic variants that display a strong association with the hazard of DKD. [17],[18],[19]

Neuropathy is one of a major complication with significant morbidity and mortality in both types of DM. [20] It can be categorized to focal mononeuropathies and generalized polyneuropathy. It should be noticed in adolescents with long duration of diabetes, even it is an infrequent finding during childhood, who may have both peripheral and autonomic DN. [4],[21] Patients with DN can be presented by apparent symptoms or it can be subclinically evident, with abnormalities acquirable only by careful experiment. DCCT reported, clinical neuropathy developed in 9.8% of patients after 5 years of diabetic onset. Based on the definition, clinical neuropathy was as an abnormal neurologic finding confirmed with peripheral sensorimotor polyneuropathy in addition either abnormal nerve conduction in at least two peripheral nerves or explicit abnormal autonomic neuropathy. [22],[23] The Rochester Diabetic Study offering the most beneficial community-based investigation of 380 diabetic subjects. In 278 patients with T2DM, 59% had some figure of neuropathy, and 45% had polyneuropathy; in 102 patients with T1DM, 66% had some figure of neuropathy, whereas 54% had polyneuropathy; polyneuropathy with peculiar involvement of the autonomic nervous system was detected in 5% of patients with T2DM and 7% of patients with T1DM. [24]

Diabetic autonomic neuropathy (DAN) has also been documented among the children with T1DM. [25] Cardiovascular autonomic neuropathy (CAN) is the most serious feature of DAN. The multicenter study of Ziegler et al. revealed that 34.3% of patients with T2DM and 25.3% of patients with T1DM had abnormal results in more than two of six autonomic activity exams. [26]

Nerve growth factor (NGF) also has an important impression in the pathogenesis of DN. [27] NGF-related to a gene family encoding proteins entitled neurotrophins. Decline in NGF synthesis may provide to the development of neuropathy, particularly in function of small fibers, which involve in pain and thermal sensation. [28]

Currently, recognition of genetic loci or genes at risk for diabetic complications is take place with multiple genetic facilities. Genetic linkage analysis and genetic association analysis are classical genetic approaches, which have been used to identify genetic aptitude variants or genes. [29] Genetic linkage analysis has been targeted to acquire the location of disease genes on the chromosome, Which are closer and stay linked during meiosis. This include the following processes: Detecting linked loci, confirming linked loci, fine mapping of confirmed loci, and finally assay genes in the linked region. [30] Dense marker map also called genetic association analysis based on common variant hypothesis has recognize genetic flair. [29] This approach used the frequency of the allele in irrelevant patients with equivalent controls. [31] Among the most important genetic markers for genetic association analysis, are single nucleotide polymorphisms (SNPs). [32] The whole human genome is a powerful method for detecting gene associated with a special disease. HapMap of the human genome introduce GWAS as a reality. [33] Genetic association-based gene mapping include the following processes: Tag SNPs, emphasize SNP association, gene detection, and then functional evaluation.

Mitochondrial DNA (mtDNA) that is located in DNA located within mitochondria is nongenomic, which is responsible for ATP production. This genome is highly dense, comprised circular double-stranded DNA larger than 16 kb. Each cell contains several hundred mitochondria, with 2-10 copies of mtDNA in each mitochondria. Genetic analysis of mtDNA, consist of its genome association and copy number evaluation. [34] Mutation in mtDNA may lead to a change in the protein-coding order, which may modify metabolism, affect several complex diseases such as DM. [35],[36],[37] Mitochondrial haplogroups and single mutations are associated with DM and a mtDNA genome-wide association evaluation inquire into a role for diabetic complications, including the development of diabetic microvascular complications (DMC). [38] This study detect that H haplotype mtDNA increase the risk of retinopathy (P = 0.0007). This finding also showed that other subtype of mitochondrial haplogroups H3, U3, and V were increase incidence of DKD. Epigenetic alterations in chromatin persuade by environmental factor also implicated in gene transcription in the progression of DMC. [39]

Environmental stimuli with interactions of gene polymorphisms impress a disease development. [40] Gene × environment interactions are valuable research in GWAS. [41] This study reveal the effects of individual factor on a complex composition that can be important for risk prognosis and benefit of environmental modification on organ health. [42],[43],[44] Gene × environment interaction study showed that the T allele rs4673 polymorphism was more prevalent in smokers with ESRD or gross proteinuria than in nonalbuminuric patients (P = 0.045). [45]

The cornerstone of this review based on the common sciences of the genetic of DMC and outline data from prior genetic studies regarding aptitude genetic and structural variants changes that affect DMC.


  Genetics and diabetic retinopathy Top


Genetic susceptibility to DR has been suggested to locate on chromosome 3 locus. [46] Further, as in Pima Indians linkage study showed that chromosome 1 may hold on to genes allow susceptibility to DR. [47] Looker et al. conducted genome-wide linkage scans, reported DR linkage to chromosomes 3 and 12 in Mexican-Americans. [48] As mentioned in [Table 1] chromosome 3 locus has been noticed in two independent linkage analysis.
Table 1: Analysis of genetic linkage for diabetic microvascular complications

Click here to view


Recent studies demonstrate that several genes, including advanced glycation end (AGE), vascular endothelial growth factor (VEGF) and ALR2, are responsible for DR. [49] It is certify that AGE and its receptor (RAGE), contribute to DMC through direct tissue damage. [50] Polymorphisms in the RAGE gene in the Caucasian population, suggest that associated DR is linked to glycosylated hemoglobin levels. [51],[52] These results have been firmly make over in other similar studies in Asian Indians. [53],[54],[55] Neovascularization of proliferative retinopathy is linked to VEGF. [56] Polymorphism in the promoter region of VEGF in Japanese and Indian populations have been associated with DR. [57],[58],[59] Further VEGF polymorphisms studies have been signify in the development of DR. [60],[61],[62],[63],[64],[65] ALR2 as a first and rate limiting enzyme of the polyol pathway is associated to DMC. [66] ALR2 gene polymorphisms have been constantly disclosed to associate with DR in various populations including Chinese, Japanese, Indians, Brazilians, and Iranians. [67],[68],[69],[70],[71],[72],[73],[74],[75],[76] Similar results have not been confirmed in other studies, such as Koreans. [77],[78] Other candidate genes, such as ACE, MTHFR, GLUT1, HP, and APOE have been implicated with DR, although limitations of sample sizes or method design, make not consistent [Table 2]. [79],[80],[81],[82],[83],[84],[85]
Table 2: Analysis of genetic association for diabetic microvascular complications

Click here to view



  Genetics and diabetic kidney disease Top


Functional polymorphisms that affect the activity of metabolic pathways may link to candidate genes for DKD, including lipid production, insulin resistance (IR), nitric oxide, renin-angiotensin, and bradykinin systems. However, genetic loci or polymorphism for DKD risk or protection has been no consistent due to phenotypic heterogeneity. [Table 1] shows list of disclosed chromosome regions for DKD.

Imperatore et al. discussed the powerful evidence of linkage to chromosome 7q and further to chromosomes 3, 9, and 20 for DKD in Pima Indians. [46] Angiotensin II type 1 receptor gene, is one of these regions which also has been found in a similar study. [116] Another genome-wide scan for DKD observed for nephropathy loci on chromosomes 3, 7p, and 18q in African-American families. [89]

Several important genes associated with DKD studies have recognized, including ACE, ENPP1, FABP2, and GLUT1. Polymorphism with I/D was reported in ACE and the development of DKD in T2DM Brazilian patients. [115] Remarkably, D allele (DD/ID) was at a greater risk for obvious DKD. [117] However, ethnic differences cause incompatible results regarding ACE I/D polymorphism with DKD in several studies. [118] IR gene can also be noted as DKD candidates. [95],[99] A feasible association between progressive DKD and the ENPP1 rs1805101 polymorphism was observed with IR. [100],[104] GLUT1 polymorphisms have also been considered as candidate risk factor for DKD due to they being associated with early kidney alterations, and also because GLUT1 functions as a glucose transporter in kidneys. As in genetic study, GLUT1 rs4673 polymorphism was more noted with smoking as an environmental factor, with persistent proteinuria than in normal populations. The CT and TT genotypes have been confirmed with a greater risk of obvious DKD among smokers. [101],[102] The DKD may also affected by 11 SNPs that located in four distinct chromosomal regions. The powerful of these association was a SNP located on chromosome 9p near FRMD3, and other three loci of SNPs were located near CHN2 and CPVL on chromosome7p, CARS on 11p, and in an intergenic region at 13q [Table 2]. This association of DKD with the 9q and 11p loci was reported in the EDIC/DCCT cohort and a recently four studies from Japan. [103],[119]


  Genetics and diabetic neuropathy Top


In the pathogenesis of DN, oxidative, and nitrosative stress play an important, as evidence display poly (ADP-ribose) polymerase (PARP) activation, is a compelling step in diabetic nerve function and metabolic pathways. Wild-type (PARP [sup+/+]) was the manifest diabetic motor and sensory nerve conduction slowing and nerve energy failure that were clearly protected in the PARP-deficient (PARP [sup−/−]) diabetes. Both endothelial and Schwann cells are the target cells of poly (ADP-ribose) accumulation. PARP inhibitors provide the potential therapeutic value of this devastating complication of diabetes. [120]

Different distribution of a VEGF gene polymorphism at promoter region (-7*C/T) between diabetic subjects with versus without neuropathy and the allele (C) allow susceptibility to DN (P = 0.02). Polymorphism of the VEGF gene at position -7*C/T may harbor functional/regulatory in gene expression. [121]

DN may associate with methylenetetrahydrofolate reductase (MTHFR) gene variants that also have been linked with vasculopathy. Yigit et al. shown a high association between the MTHFR gene C677T mutation and DPN. [122]

Diabetic microangiopathy may involve in the aldose reductase gene, with the most plausible data recognizing a (CA)n repeat microsatellite allele (Z−2) in a functional role in gene expression. The Z−2/Z−2 genotype is significantly associated with the development of DAN as a pupillary abnormality, in adolescent Australian patients with type 1 diabetes. [123]


  Conclusions Top


Extensive development of research on the genetic determinants of DMC has been observed in past two decades. Although a single candidate gene has been favorite, but several, possibly interlinked, genes are likely to be implicated. Genetic variants with linkage studies and candidate gene approaches points out many potential genetic susceptibility to disease. However, procreation of these results has often been conflicting due to different factors, e.g., research design or ethnicity. However, a few compatible associations implicating variants in the ALR2, VEGF, and RAGE genes have been described in genetic association analyses. The effective recognition of the disease at an early stage, result to changes in dietary behavior and lifestyle, is important for disease prevention and progression. It is anticipated that specifications of the genetic factors implicated in the DMC will lead to the perception of the molecular pathogenesis and the advancement of novel therapeutic options. Although mtDNA and nuclear DNA are differing, there is proportionate interaction and expression between the gene outputs of the mitochondria and nuclear genomes.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: A population study using record linkage. Diabetes Care 2000;23:1103-7.  Back to cited text no. 1
    
2.
Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol 2012;60:428-31.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.
Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983;25:496-501.  Back to cited text no. 3
    
4.
Donaghue KC, Silink M. Diabetic neuropathy in childhood. Diabetes Nutr Metab 1999;12:154-60.  Back to cited text no. 4
    
5.
Cahill GF Jr, Etzwiler LD, Freinkel N. Editorial: "Control" and diabetes. N Engl J Med 1976;294:1004-5.  Back to cited text no. 5
    
6.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.  Back to cited text no. 6
    
7.
Pyke DA, Tattersall RB. Diabetic retinopathy in identical twins. Diabetes 1973;22:613-8.  Back to cited text no. 7
    
8.
Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46:1829-39.  Back to cited text no. 8
    
9.
Alcolado J. Genetics of diabetic complications. Lancet 1998;351:230-1.  Back to cited text no. 9
    
10.
The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.  Back to cited text no. 10
    
11.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.  Back to cited text no. 11
    
12.
Rocco MV, Berns JS. KDOQI in the era of global guidelines. Am J Kidney Dis 2009;54:781-7.  Back to cited text no. 12
    
13.
Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-ß-D-glucosaminidase. Kidney Int 2011;79:464-70.  Back to cited text no. 13
    
14.
Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL, Kshirsagar AV. Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 2013;27:123-7.  Back to cited text no. 14
    
15.
Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-93.  Back to cited text no. 15
    
16.
Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-5.  Back to cited text no. 16
    
17.
Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012;8:e1002921.  Back to cited text no. 17
    
18.
Mueller PW, Rogus JJ, Cleary PA, Zhao Y, Smiles AM, Steffes MW, et al. Genetics of kidneys in diabetes (GoKinD) study: A genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 2006;17:1782-90.  Back to cited text no. 18
    
19.
Igo RP Jr, Iyengar SK, Nicholas SB, Goddard KA, Langefeld CD, Hanson RL, et al. Genomewide linkage scan for diabetic renal failure and albuminuria: The FIND study. Am J Nephrol 2011;33:381-9.  Back to cited text no. 19
    
20.
Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989;38:1456-61.  Back to cited text no. 20
    
21.
Donaghue KC, Bonney M, Simpson JM, Schwingshandl J, Fung AT, Howard NJ, et al. Autonomic and peripheral nerve function in adolescents with and without diabetes. Diabet Med 1993;10:664-71.  Back to cited text no. 21
    
22.
Karavanaki K, Baum JD. Prevalence of microvascular and neurologic abnormalities in a population of diabetic children. J Pediatr Endocrinol Metab 1999;12:411-22.  Back to cited text no. 22
    
23.
Vinik AI, Pittenger GL, McNitt P, Stansberry KB. Diabetic neuropathies. An overview of clinical aspects, pathogenesis and treatment. In: Le Roith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. 2 nd ed. Philadelphia: Lipincott, Williams & Wilkins; 2000. p. 910-34.  Back to cited text no. 23
    
24.
Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24.  Back to cited text no. 24
    
25.
Sosenko JM, Boulton AJ, Kubrusly DB, Weintraub JK, Skyler JS. The vibratory perception threshold in young diabetic patients: Associations with glycemia and puberty. Diabetes Care 1985;8:605-7.  Back to cited text no. 25
    
26.
Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992;6:49-57.  Back to cited text no. 26
    
27.
Vinik AI, Newlon PG, Lauterio TJ. Nerve survival and regeneration in diabetes. Diabetes Metab Rev 1995;3:139-43.  Back to cited text no. 27
    
28.
Rich KM, Luszczynski JR, Osborne PA, Johnson EM Jr. Nerve growth factor protects adult sensory neurons from cell death and atrophy caused by nerve injury. J Neurocytol 1987;16:261-8.  Back to cited text no. 28
    
29.
Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-7.  Back to cited text no. 29
    
30.
Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002;298:2345-9.  Back to cited text no. 30
    
31.
Hodge SE. What association analysis can and cannot tell us about the genetics of complex disease. Am J Med Genet 1994;54:318-23.  Back to cited text no. 31
    
32.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn′s disease. Nature 2001;411:603-6.  Back to cited text no. 32
    
33.
International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-320.  Back to cited text no. 33
    
34.
Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-7.  Back to cited text no. 34
    
35.
Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res 2003;5:491-504.  Back to cited text no. 35
    
36.
Hagiwara M, Yamagata K, Capaldi RA, Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006;69:1146-52.  Back to cited text no. 36
    
37.
Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-5.  Back to cited text no. 37
    
38.
Achilli A, Olivieri A, Pala M, Hooshiar Kashani B, Carossa V, Perego UA, et al. Mitochondrial DNA backgrounds might modulate diabetes complications rather than T2DM as a whole. PLoS One 2011;6:e21029.  Back to cited text no. 38
    
39.
Gray SG, De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 2005;21:416-33.  Back to cited text no. 39
    
40.
Rutter M, Moffitt TE, Caspi A. Gene-environment interplay and psychopathology: Multiple varieties but real effects. J Child Psychol Psychiatry 2006;47:226-61.  Back to cited text no. 40
    
41.
Le Marchand L, Wilkens LR. Design considerations for genomic association studies: Importance of gene-environment interactions. Cancer Epidemiol Biomarkers Prev 2008;17:263-7.  Back to cited text no. 41
    
42.
Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005;6:287-98.  Back to cited text no. 42
    
43.
Chapman J, Clayton D. Detecting association using epistatic information. Genet Epidemiol 2007;31:894-909.  Back to cited text no. 43
    
44.
Thomas DC, Witte JS, Greenland S. Dissecting effects of complex mixtures: Who′s afraid of informative priors? Epidemiology 2007;18:186-90.  Back to cited text no. 44
    
45.
Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. J Nephrol 2005;18:733-8.  Back to cited text no. 45
    
46.
Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998;47:821-30.  Back to cited text no. 46
    
47.
Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. Diabetes 2007;56:1167-73.  Back to cited text no. 47
    
48.
Looker HC, Nelson RG, Chew E, Klein R, Klein BE, Knowler WC, et al. Genome-wide linkage analyses to identify Loci for diabetic retinopathy. Diabetes 2007;56:1160-6.  Back to cited text no. 48
    
49.
Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2006;114:275-94.  Back to cited text no. 49
    
50.
Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003;75:95-108.  Back to cited text no. 50
    
51.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.  Back to cited text no. 51
    
52.
Lindholm E, Bakhtadze E, Sjögren M, Cilio CM, Agardh E, Groop L, et al. The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia 2006;49:2745-55.  Back to cited text no. 52
    
53.
Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001;50:1505-11.  Back to cited text no. 53
    
54.
Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J Diabetes Complications 2002;16:391-4.  Back to cited text no. 54
    
55.
Ramprasad S, Radha V, Mathias RA, Majumder PP, Rao MR, Rema M. Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India. Eye (Lond) 2007;21:395-401.  Back to cited text no. 55
    
56.
Sydorova M, Lee MS. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res 2005; 37:188-90.  Back to cited text no. 56
    
57.
Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.  Back to cited text no. 57
    
58.
Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006;12:336-41.  Back to cited text no. 58
    
59.
Uthra S, Raman R, Mukesh BN, Rajkumar SA, Padmaja KR, Paul PG, et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet 2008;29:11-5.  Back to cited text no. 59
    
60.
Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004;53:861-4.  Back to cited text no. 60
    
61.
Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:3611-6.  Back to cited text no. 61
    
62.
Szaflik JP, Wysocki T, Kowalski M, Majsterek I, Borucka AI, Blasiak J, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008;246:39-43.  Back to cited text no. 62
    
63.
Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005;333:679-85.  Back to cited text no. 63
    
64.
Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, et al. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: The DCCT/EDIC genetics study. Diabetes 2007;56:2161-8.  Back to cited text no. 64
    
65.
Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant 2007;22:827-32.  Back to cited text no. 65
    
66.
Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 1989;30:2285-92.  Back to cited text no. 66
    
67.
Ko BC, Lam KS, Wat NM, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995;44:727-32.  Back to cited text no. 67
    
68.
Fujisawa T, Ikegami H, Kawaguchi Y, Yamato E, Nakagawa Y, Shen GQ, et al. Length rather than a specific allele of dinucleotide repeat in the 5′ upstream region of the aldose reductase gene is associated with diabetic retinopathy. Diabet Med 1999;16:1044-7.  Back to cited text no. 68
    
69.
Ichikawa F, Yamada K, Ishiyama-Shigemoto S, Yuan X, Nonaka K. Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5′-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with type 2 diabetes mellitus. Diabet Med 1999;16:744-8.  Back to cited text no. 69
    
70.
Ikegishi Y, Tawata M, Aida K, Onaya T. Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. Life Sci 1999;65:2061-70.  Back to cited text no. 70
    
71.
Olmos P, Futers S, Acosta AM, Siegel S, Maiz A, Schiaffino R, et al. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res Clin Pract 2000;47:169-76.  Back to cited text no. 71
    
72.
Lee SC, Wang Y, Ko GT, Critchley JA, Ng MC, Tong PC, et al. Association of retinopathy with a microsatellite at 5′ end of the aldose reductase gene in Chinese patients with late-onset type 2 diabetes. Ophthalmic Genet 2001;22:63-7.  Back to cited text no. 72
    
73.
Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet 2003;24:41-8.  Back to cited text no. 73
    
74.
Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003;26:2410-5.  Back to cited text no. 74
    
75.
Richeti F, Noronha RM, Waetge RT, de Vasconcellos JP, de Souza OF, Kneipp B, et al. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis 2007;13:740-5.  Back to cited text no. 75
    
76.
Rezaee MR, Amiri AA, Hashemi-Soteh MB, Daneshvar F, Emady-Jamaly R, Jafari R, et al. Aldose reductase C-106T gene polymorphism in type 2 diabetics with microangiopathy in Iranian individuals. Indian J Endocrinol Metab 2015;19:95-9.  Back to cited text no. 76
    
77.
Park HK, Ahn CW, Lee GT, Kim SJ, Song YD, Lim SK, et al. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;55:151-7.  Back to cited text no. 77
    
78.
Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: Relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 2003;61:133-6.  Back to cited text no. 78
    
79.
Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997;20:1304-9.  Back to cited text no. 79
    
80.
Liu ZH, Guan TJ, Chen ZH, Li LS. Glucose transporter (GLUT1) allele (XbaI-) associated with nephropathy in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1843-8.  Back to cited text no. 80
    
81.
Matsumoto A, Iwashima Y, Abiko A, Morikawa A, Sekiguchi M, Eto M, et al. Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 2000;50:195-202.  Back to cited text no. 81
    
82.
Maeda M, Yamamoto I, Fukuda M, Nishida M, Fujitsu J, Nonen S, et al. MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. Diabetes Care 2003;26:547-8.  Back to cited text no. 82
    
83.
Koda Y, Soejima M, Yamagishi S, Amano S, Okamoto T, Inagaki Y, et al. Haptoglobin genotype and diabetic microangiopathies in Japanese diabetic patients. Diabetologia 2002;45:1039-40.  Back to cited text no. 83
    
84.
Nakhoul FM, Marsh S, Hochberg I, Leibu R, Miller BP, Levy AP. Haptoglobin genotype as a risk factor for diabetic retinopathy. JAMA 2000;284:1244-5.  Back to cited text no. 84
    
85.
Amiri AA, Hashemi-Soteh MB, Haghshenas MR, Daneshvar F, Rastegar A, Farazmand T. Haptoglobin polymorphism in individuals with type 2 diabetic microangiopathy. N Am J Med Sci 2013;5:529-35.  Back to cited text no. 85
    
86.
Elbein SC, Hasstedt SJ. Quantitative trait linkage analysis of lipid-related traits in familial type 2 diabetes: Evidence for linkage of triglyceride levels to chromosome 19q. Diabetes 2002;51:528-35.  Back to cited text no. 86
    
87.
Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The family investigation of nephropathy and diabetes (FIND). Diabetes 2007;56:1577-85.  Back to cited text no. 87
    
88.
Rogus JJ, Poznik GD, Pezzolesi MG, Smiles AM, Dunn J, Walker W, et al. High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: Discordant sibpair approach. Diabetes 2008;57:2519-26.  Back to cited text no. 88
    
89.
Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, et al. A genome scan for diabetic nephropathy in African Americans. Kidney Int 2004;66:1517-26.  Back to cited text no. 89
    
90.
Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 2003;52:2848-53.  Back to cited text no. 90
    
91.
Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002;62:2176-83.  Back to cited text no. 91
    
92.
Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, et al. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int 2006;69:129-36.  Back to cited text no. 92
    
93.
Malhotra A, Wolford JK; American Diabetes Association GENNID Study Group. Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study. Diabetes 2005;54:3007-14.  Back to cited text no. 93
    
94.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn′s disease. Nature 2001;411:603-6.  Back to cited text no. 94
    
95.
Groop L, Ekstrand A, Forsblom C, Widén E, Groop PH, Teppo AM, et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:642-7.  Back to cited text no. 95
    
96.
Hoover KB, Bryant PJ. The genetics of the protein 4.1 family: Organizers of the membrane and cytoskeleton. Curr Opin Cell Biol 2000;12:229-34.  Back to cited text no. 96
    
97.
Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 1998;18:319-24.  Back to cited text no. 97
    
98.
Weber JL. Human DNA polymorphisms and methods of analysis. Curr Opin Biotechnol 1990;1:166-71.  Back to cited text no. 98
    
99.
Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993;342:883-7.  Back to cited text no. 99
    
100.
Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999;48:1881-4.  Back to cited text no. 100
    
101.
Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. J Nephrol 2005;18:733-8.  Back to cited text no. 101
    
102.
Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009;58:1403-10.  Back to cited text no. 102
    
103.
Maeda S, Araki S, Babazono T, Toyoda M, Umezono T, Kawai K, et al. Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 2010;59:2075-9.  Back to cited text no. 103
    
104.
Canani LH, Ng DP, Smiles A, Rogus JJ, Warram JH, Krolewski AS. Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes 2002;51:1188-93.  Back to cited text no. 104
    
105.
Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6.  Back to cited text no. 105
    
106.
McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488-91.  Back to cited text no. 106
    
107.
Bowden DW. Genetics of diabetes complications. Curr Diab Rep 2002;2:191-200.  Back to cited text no. 107
    
108.
Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-7.  Back to cited text no. 108
    
109.
Wagenknecht LE, Bowden DW, Carr JJ, Langefeld CD, Freedman BI, Rich SS. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 2001;50:861-6.  Back to cited text no. 109
    
110.
Hodge SE, Anderson CE, Neiswanger K, Sparkes RS, Rimoin DL. The search for heterogeneity in insulin-dependent diabetes mellitus (IDDM): Linkage studies, two-locus models, and genetic heterogeneity. Am J Hum Genet 1983;35:1139-55.  Back to cited text no. 110
    
111.
Risch N. Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am J Hum Genet 1990;46:229-41.  Back to cited text no. 111
    
112.
Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002;298:2345-9.  Back to cited text no. 112
    
113.
Brookes AJ. The essence of SNPs. Gene 1999;234:177-86.  Back to cited text no. 113
    
114.
Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007;8:657-62.  Back to cited text no. 114
    
115.
Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 2005;54:3326-30.  Back to cited text no. 115
    
116.
Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: Results of novel discordant sib-pair analysis. Diabetes 1998;47:1164-9.  Back to cited text no. 116
    
117.
Canani LH, Costa LA, Crispim D, Gonçalves Dos Santos K, Roisenberg I, Lisbôa HR, et al. The presence of allele D of angiotensin-converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of type 2 diabetes. Diabet Med 2005;22:1167-72.  Back to cited text no. 117
    
118.
Ng DP, Tai BC, Koh D, Tan KW, Chia KS. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 2005;48:1008-16.  Back to cited text no. 118
    
119.
Riad A, Zhuo JL, Schultheiss HP, Tschöpe C. The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr Opin Nephrol Hypertens 2007;16:22-6.  Back to cited text no. 119
    
120.
Obrosova IG, Li F, Abatan OI, Forsell MA, Komjáti K, Pacher P, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004;53:711-20.  Back to cited text no. 120
    
121.
Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, et al. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep 2010;37:3625-30.  Back to cited text no. 121
    
122.
Yigit S, Karakus N, Inanir A. Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy. Mol Vis 2013;19:1626-30.  Back to cited text no. 122
    
123.
Donaghue KC, Margan SH, Chan AK, Holloway B, Silink M, Rangel T, et al. The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. Diabet Med 2005;22:1315-20.  Back to cited text no. 123
    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Genetics and dia...
Genetics and dia...
Genetics and dia...
Conclusions
References
Article Tables

 Article Access Statistics
    Viewed1862    
    Printed110    
    Emailed0    
    PDF Downloaded2896    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]